Skip to main content
Premium Trial:

Request an Annual Quote

BD Buys Sirigen

NEW YORK (GenomeWeb News) – Becton Dickinson announced today that it has acquired Sirigen, a maker of polymer dyes that are used in flow cytometry and other technologies.

Hampshire, UK-based Sirigen has developed the High Sensitivity Fluorescence detection technology with applications in the diagnostics and life science research markets. The firm's technology is platform agnostic, and according to its website, can facilitate high-volume screening for personalized medicine purposes and can be used to boost the performance of existing molecular diagnostics tests and immunoassays.

Financial terms of the deal were not disclosed. BD said that it expects the acquisition to be dilutive to its full-year 2012 earnings per share by approximately $.01 on a GAAP basis.

"This new technology is a natural complement to our instrument platforms and reagent portfolio," Alberto Mas, president of the BD Biosciences segment of BD, said in a statement. "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.